Ibuprofen Safety at the Golden Anniversary: Are all NSAIDs the Same? A Narrative Review
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Ibuprofen first came to market about 50 years ago and rapidly moved to over-the-counter (OTC) sales. In April 2019, the National Agency for the Safety of Medicines and Health Products (ANSM) of France issued a warning for NSAID uses by patients with infectious diseases based on an analysis of 20 years of real-world safety data on ibuprofen and ketoprofen. Nevertheless, ibuprofen remains a mainstay in the analgesic armamentarium and with numerous randomized clinical trials, head-to-head studies, and decades of clinical experience. The authors offer a review of the safety of ibuprofen and how it may differ from other NSAIDs. Ibuprofen is associated with certain well-known gastrointestinal adverse effects that are related to dose and patient population. Among nonsteroidal anti-inflammatory drugs (NSAIDs), ibuprofen has a comparatively low risk of cardiovascular adverse effects. It has been associated with renal and hepatic adverse effects, which appear to depend on dose, concomitant medications, and patient population. The association of ibuprofen with infections is more complex in that it confers risk in some situations but benefits in others, the latter in cystic fibrosis. Emerging interest in the literature is providing evidence of the role of ibuprofen as a possible endocrine disrupter as well as its potential antiproliferative effects for cancer cells. Taken altogether, ibuprofen has a favorable safety profile and is an effective analgesic for many acute and chronic pain conditions, although it-like other NSAIDs-is not without risk. After 50 years, evidence is still emerging about ibuprofen and its unique safety profile among NSAIDs. FUNDING: The Rapid Service Fee was funded by Abbott Established Pharmaceuticals Division (EPD).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Paracetamol: Past, Present, and Future
Prescott, L. F. (2000) · American Journal of Therapeutics · doi:10.1097/00045391-200007020-00011 · Cited by 233
Non-prescription (OTC) oral analgesics for acute pain - an overview of Cochrane reviews
Moore, R. A., Wiffen, P. J., Derry, S., Maguire, T., Roy, Y. M., & Tyrrell, L. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010794.pub2 · Cited by 174 · cited 1×
“In an overview of systematic reviews and meta-analyses of various OTC analgesics, ibuprofen’s and other pain relievers’ rates of adverse events were similar to placebo when taken at therapeutic doses for a few days to treat acute pain [28].”
BackgroundRuschitzka, F., Borer, J. S., Krum, H., Flammer, A. J., Yeomans, N. D., Libby, P., Lüscher, T. F., Solomon, D. H., Husni, M. E., Graham, D. Y., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx508 · Cited by 130
Cited by
Milani, G. P., Nicolini, G., Cananzi, M., Spiezia, L., & Vidal, E. (2026) · Children · doi:10.3390/children13010071 · Cited by 5
Metadata
- Authors
- Varrassi, G., Pergolizzi, J. V., Dowling, P., & Paladini, A.
- Venue
- Advances in Therapy
- Published
- 2019-11-08
- Volume
- 37
- Issue
- 1
- Pages
- 61-82
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- OpenAlex
- W2985886213
- Cited by
- 180
- References
- 4
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ibuprofen Safety at the Golden Anniversary: Are all NSAIDs the Same? A Narrative Review. https://app.cochat.ai/papers/10.1007/s12325-019-01144-9
- The paper
- Varrassi, G., Pergolizzi, J. V., Dowling, P., & Paladini, A. (2020). Ibuprofen Safety at the Golden Anniversary: Are all NSAIDs the Same? A Narrative Review. Advances in Therapy. https://doi.org/10.1007/s12325-019-01144-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.